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Since antimicrobial resistance among uropathogens against current ﬁrst line agents has
affected the management of severe urinary tract infection, we determined the likelihood
that antibiotic regimens achieve bactericidal pharmacodynamic exposures using Monte
Carlo simulation for ﬁve antimicrobials (ciproﬂoxacin, ceftriaxone, piperacillin/tazobactam,
ertapenem, and meropenem) commonly prescribed as initial empirical treatment of inpa-
tients with severe community acquired urinary tract infections. Minimum inhibitory
concentration determination by Etest was performed for 205 Brazilian community urinary
tract infection Escherichia coli strains from 2008 to 2012 and 74 E. coli bloodstream strains
recovered from a surveillance study. Pharmacodynamic exposure was modeled via a 5000
subject Monte Carlo simulation. All isolates were susceptible to ertapenem and meropenem.
Piperacillin/tazobactam, ceftriaxone and ciproﬂoxacin showed 100%, 97.5% and 83.3% sus-
ceptibility among outpatient isolates and 98.6%, 75.7% and 64.3% among inpatient isolates,
respectively. Against outpatient isolates, all drugs except ciproﬂoxacin (82.7% in aggressive
and  77.6% in conservative scenarios) achieved high cumulative fraction of response: car-
bapenems and piperacillin/tazobactam cumulative fraction of responses were close to 100%,
and ceftriaxone cumulative fraction of response was 97.5%. Similar results were observed
against inpatients isolates for carbapenems (100%) and piperacillin/tazobactam (98.4%),
whereas ceftriaxone achieved only 76.9% bactericidal cumulative fraction of response and
ciproﬂoxacin 61.9% (aggressive scenario) and 56.7% (conservative scenario) respectively.
Based on this model, standard doses of beta-lactams were predicted to deliver sufﬁcient
pharmacodynamic exposure for outpatients. However, ceftriaxone should be avoided forinpatients and ciproﬂoxacin empirical prescription should be avoided in both inpatients
and outpatients with complicated urinary tract infection.
© 2014 Elsevier Editora Ltda. All rights reserved.
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ntroduction
rinary tract infection (UTI) is the most common bacterial
nfection and acute pyelonephritis is a severe form of UTI with
ymptoms that range from mild discomfort to life threatening
llness or death.1,2 The incidence of pyelonephritis requir-
ng hospitalization is 3–4 cases per 10,000 population among
omen and 1–2 cases per 10,000 population among men, with
n estimation of direct and indirect costs of US$ 2.1 billion
nd in hospital mortality of 7.3 per 1000 hospitalizations for
emales and 16.5 per 1000 for males.2–4 The bacteriology of
yelonephritis is similar to the other UTIs, the majority of
hem being caused by Escherichia coli.3,5
The management of UTIs is usually empirical, based on
he predictable spectrum of etiologic agents and their sus-
eptibility patterns. Due to the emergence of antimicrobial
esistance among uropathogens, the safety and effectiveness
f empirical therapy have been affected.6 Recently, ex vivo
harmacodynamic (Pd) models (based on Monte Carlo sim-
lation) have been used to help determine the best regimens
r dosages for a speciﬁc patient population, by integrating an
gent’s in vitro potency distribution (i.e., minimum inhibitory
oncentrations [MICs]) with the pharmacokinetic (Pk) proﬁle
f a drug.7
Regional surveillance studies show that antimicrobial
esistance against currently prescribed ﬁrst line agents
trimethoprim/sulfamethoxazole and ciproﬂoxacin) for treat-
ent of community acquired UTIs in Brazil is increasing.8,9
ince the resistance patterns of E. coli strains caus-
ng UTI vary considerably between regions and countries,
peciﬁc treatment regimens based on local susceptibil-
ty patterns are necessary.5,9 The aim of this study was
o compare the pharmocodynamic proﬁles of ﬁve antimi-
robials (ciproﬂoxacin, ceftriaxone, piperacillin/tazobactam,
rtapenem and meropenem) commonly prescribed as initial
mpirical therapy in hospitals for the treatment of inpa-
ients with community acquired UTIs, usually complicated or
yelonephritis.
aterials  and  methods
icrobiology
acterial  isolates
he present study included a total of 279 bacterial isolates; 100
solates of outpatients stored at the culture collection of the
pecial Laboratory of Clinical Microbiology (LEMC) since 2008,
05 isolates of outpatients prospectively collected between
ugust and November 2012, and 74 nosocomial isolates from
he ﬁrst bacteremia at 16 hospitals in Brazil participants of
he BrSCOPE study.10 All isolates were identiﬁed with the BD
hoenix 5.1TM (Becton Dickinson, Sparks, MD 21152, USA)
nd/or biochemical identiﬁcation methods. Only one isolate
er patient was included in the study.inimal  inhibitory  concentration  (MIC)  testing
he MIC  was determined by epsilometric test (Etest®,
ioMérieux, Marcy  l’Etoile, France) for ertapenem (0.002–32),4;1 8(5):512–517 513
meropenem (0.002–32), ciproﬂoxacin (0.002–32), ceftriaxone
(0.016–256) and piperacillin/tazobactam (0.016–256), following
the recommendations of the manufacturer. Quality control
was performed by testing E. coli ATCC 25,922® and P. aeruginosa
ATCC® 27,853, with all results within expected ranges.
Samples were subcultured onto blood agar and then onto
MacConkey agar to ensure viability and purity. Individual
colonies were picked from 18 to 24 h plates and suspended in
0.85% saline to a turbidity of a 0.5 McFarland standard. Cotton
swabs were used to transfer the inoculum to the plates with
Mueller Hinton agar (Oxoid, Basingstoke, Inglaterra), which
were dried before the Etest® strips were applied. For each
strain, the ﬁve antibiotics were arranged in a single plate.
Plates were incubated for 18–24 h at 35 ◦C. Readings and inter-
pretations were performed according to National Committee
for Clinical Laboratory Standards (NCCLS).11
Pk  and  Pd  data
Pk  data
Pk data were obtained from previously published studies in
healthy volunteers.12–14 For studies to be considered, they had
to be conducted in at least 10 healthy volunteers, describ-
ing the assay used to determine drug concentrations, and
present mean and standard deviation results for the total body
clearance in liters per hour (CL), volume of distribution of the
central compartment (Vc) and other pertinent Pk parameters.
Because published reports with the above characteristics were
not identiﬁed for piperacillin/tazobactam and ceftriaxone, Pk
data for these drugs were taken from published studies15,16 in
critical patients (no studies describing the covariance matrix
in healthy volunteers). The Pk data was then used in the Monte
Carlo simulation models. A 5000 patient Monte Carlo simula-
tion (Oracle Crystal Ball Fusion Edition, 2010) was conducted to
calculate estimates of the amount of time in which the free or
non-protein-bound drug concentration exceeds the MIC  of the
organism (fT > MIC) or the AUC/MIC ratio for each antibiotic
regimen/bacterial population combination. The simulations
were conducted as previously published.17,18 Drug dosages
chosen were based on the following commonly prescribed
regimens, administered as 30-min intravenous (IV) infusions:
ertapenem 1 g every 24 h (q24h), meropenem 1 g every 8 h
(q8h), piperacillin/tazobactam 4.5 g every 8 h (q8h), ceftriaxone
1 g every 12 h (q12h) and ciproﬂoxacin 400 mg  every 12 h (q12h).
Pd exposures, as measured by fT > MIC, were simulated for all
beta-lactam regimens against all pathogen groups. A two  com-
partment IV bolus equation was used to calculate % fT > MIC
for the beta lactams. For ciproﬂoxacin, the total drug AUC was
calculated as the daily dose divided by the total body clearance
(ClT).
Pd  model
Values for fT > MIC and AUC/MIC were plotted on frequency
curves for further analysis. The probabilities of obtaining a
fT > MIC of 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, and
100% were calculated for all the beta-lactams at increasing
MICs in doubling dilutions. Pd targets of 40% fT > MIC  and
50% fT > MIC were considered bactericidal for carbapenems
and for ceftriaxone and piperacillin/tazobactam, respectively.
We  also calculated the cumulative fT > MIC of beta-lactams,
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Table 1 – MIC  distribution for outpatient E. coli (OEC) and inpatient E. coli (IEC) included in this study.
Bacterial group (n) and antimicrobial Percentage (%) of bacteria at each MIC value (mg/L)
0.008 0.016 0.032 0.06 0.125 0.25 0.5 1 2 4 8 16 32 >32
OEC (205)
Ertapenem 88 10 1 0 0 1 0 0 0 0 0 0 0 0
Meropenem 12 87 1 0 0 0 0 0 0 0 0 0 0 0
Ceftriaxone 2 4 58 24 9 1 0 0 0 0 1 0 0 1
Piperacillin/tazobactam 0 0 0 0 0 0 2 24 63 10 1 0 0 0
Ciproﬂoxacin 35 37 1 3 0 6 1 1 0 1 1 14 0 0
IEC (74)
Ertapenem 74 18 4 4 0 0 0 0 0 0 0 0 0 0
Meropenem 14 79 6 0 1 0 0 0 0 0 0 0 0 0
Ceftriaxone 0 13 46 13 0 1 0 1 1 3 4 7 3 8
0 
0 Piperacillin/tazobactam 0 0 0 
Ciproﬂoxacin 27 26 3 
previously proposed as Pd threshold for UTI. Microbiologi-
cal cure were achieved attaining a cumulative fT > MIC above
30 h.19 The probability for achieving a total AUC/MIC ratio
greater than or equal to 62.5, 75, 100, 125, and 150 were cal-
culated for ciproﬂoxacin. The Pd target of AUC/MIC at least
62.5 (conservative scenario, half of the target for bloodstream
infection) and 125 (aggressive scenario, similar to the target
for bloodstream infection) were chosen as a Pd breakpoint for
ciproﬂoxacin. These probabilities of target attainment were
applied to the MIC  distributions for the above pathogens to
calculate the cumulative fraction of response (CFR).
Results
In  vitro  activity
Table 1 summarizes the results of the in vitro suscepti-
bility testing. The resistance proﬁle of outpatient isolates
from 2008 to 2012 was similar. All isolates were susceptible
to ertapenem and meropenem (MIC range 0.008–0.25 g/mL
and MIC  range 0.008–0.032 g/mL, respectively); 100% of
outpatient isolates (MIC range 0.5–8 g/mL) and 98.6% of
inpatient isolates (MIC range 0.25–256 g/mL) showed sus-
ceptibility to piperacillin/tazobactam. Higher resistance rates
against ceftriaxone were observed for inpatient E. coli
Table 2 – Cumulative fraction of response (CFR) at varying % fT >
inpatient E. coli isolates from Brazil.
Isolates (no.)/antimicrobial 
20% 30% 40% 
Outpatient E. coli isolates (205)
Ertapenem 1 g q24h 100% 100% 99.99% 
Meropenem 1 g q8h 100% 100% 100% 
Ceftriaxone 1 g q12h 98.03% 97.91% 97.72% 
Piperacillin/tazobactam 4.5 g q8h 100% 100% 99.99% 
Inpatient E. coli isolates (74)
Ertapenem 1 g q24h 100% 100% 100% 
Meropenem 1 g q8h 100% 100% 100% 
Ceftriaxone 1 g q12h 88.43% 82.78% 79.38% 
Piperacillin/tazobactam 4.5 g q8h 98.61% 98.57% 98.57% 0 1 0 29 56 13 0 0 0 1
0 6 3 0 0 0 6 3 26 0
(75.7% susceptibility, MIC range 0.016–256 g/mL) when com-
pared to outpatient E. coli (97.5% susceptibility, MIC  range
0.008–256 g/mL). Among the antibiotics tested, ciproﬂoxacin
had the lowest susceptibility rates against the outpatient
E. coli (83.3%, MIC  range 0.008–0.032 g/mL) and inpatient E. coli
(64.3%, MIC range 0.008–32 g/mL).
Pd  target  attainment
The Probability of Target Attainment (PTA) for beta-lactams
and ciproﬂoxacin over a range of MICs is indicated in Fig. 1.
The CFRs for each beta-lactam at varying targets for % fT > MIC
are listed in Table 2 and the CFR for ciproﬂoxacin at AUC/MIC
target of 62.5–150 is presented in Table 3. Carbapenems
demonstrated high likelihood of achieving the bactericidal
breakpoint of 40% fT > MIC and piperacillin/tazobactam at 50%
fT > MIC in both scenarios. In contrast, ceftriaxone achieved
a CFR superior to 95% only against outpatient isolates.
Ciproﬂoxacin had poor CFR against outpatient (82.7%, 77.6%)
and inpatient (61.9%, 56.7%) isolates at the target exposure of
total AUC/MIC > 62.5 and AUC/MIC > 125, respectively.
Considering a treatment duration of seven days, the
cumulative fT > MIC superior to 30 h was achieved at
MIC concentration of 8 g/mL for ceftriaxone, 8 g/mL
for meropenem, 1 g/mL for ertapenem and 64 g/mL for
piperacillin/tazobactam.
 MIC  for beta-lactams against outpatient E. coli and
CFR at varying % fT > MIC exposures
50% 60% 70% 80% 90% 100%
99.75% 99.53% 99.51% 99.27% 98.42% 98.81%
100% 100% 100% 100% 100% 100%
97.50% 96.09% 92.49% 86.64% 79.37% 74.24%
99.87% 98.87% 97.88% 95.27% 93.05% 90.11%
100% 100% 100% 98.85% 95.89% 95.46%
100% 100% 100% 100% 100% 100%
76.95% 74.71% 71.48% 67.02% 61.46% 57.65%
98.44% 97.47% 96.53% 94.04% 91.84% 88.94%
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Fig. 1 – Probability of Target Attainment (PTA) for beta-lactams and ciproﬂoxacin over minimum inhibitory concentration
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iscussion
ncreasing rates of resistance to antimicrobials commonly
sed for treating UTIs caused by E. coli among outpatients has
een reported in recent years.20 In this context, this study
ompared the antimicrobial susceptibility of community-
cquired UTI E. coli strains between two periods, since local
usceptibility patterns are essential for appropriate antimicro-
ial prescribing. The study also included nosocomial isolates
rom the ﬁrst bacteremia episode. Despite high variability in
he origin of bacteremia reported in the literature, the uri-
ary tract is one of the most frequent sources for E. coli
acteremia.21 For this reason, the authors considered the
nclusion of these isolates in the study as relevant.
The sensitivity proﬁle of outpatient E. coli was similar
etween 2008 and 2012. For ciproﬂoxacin, local surveil-
ance studies on uropathogens in community-acquired
nfections9,22 also found decreased susceptibility pattern
f outpatient E. coli, especially since the year 2000. Our
resent results are similar to those described locally by
ocha et al.,22 which obtained 82.2% in isolates of 2009. For
ther antimicrobials tested, our study showed results simi-
ar to the SENTRY study: low prevalence of ceftriaxone and
iperacillin/tazobactam resistance and no resistance against
arbapenems.9
The Monte Carlo Simulation has already been used
o forecast the efﬁcacy of different therapeutic regimens
Table 3 – Cumulative fraction of response (CFR) for varying tota
outpatient E. coli and inpatient E. coli isolates from Brazil.
Isolates (no.) CF
62.5 75 
Outpatient E. coli (205) 82.71% 82.32% 
Inpatient E. coli (74) 61.9% 61.26% in multiple scenarios, such as bloodstream infections,
community-acquired pneumonia and ventilator-associated
pneumonia.17,23,24 To the best of our knowledge, our study is
the ﬁrst report to apply the Monte Carlo Simulation evaluating
the likelihood of achieving bactericidal Pd targets in UTIs.
As for the Pd targets adopted, few studies have established
speciﬁc Pd thresholds for UTI. Deguchi et al.,25 determined the
Pd target of levoﬂoxacin for microbiological cure in patients
with complicated UTI based on the plasma concentration of
the drug and the threshold of AUC/MIC for predicting microbi-
ological cure was lower than those in other kind of infections.
No studies correlating a Pd target of ciproﬂoxacin plasma
concentration and microbiological cure for UTI were found
in our review. Since ciproﬂoxacin and levoﬂoxacin are ﬂuo-
roquinolones and targets within antibiotic classes tend to be
similar, we proposed the two scenarios previously described:
an aggressive and a conservative one for ciproﬂoxacin.
With respect to beta-lactam antibiotics, a cumulative
fT > MIC around 30 h was correlated to maximum cure rate
for serum aminopenicillin concentration.19 Unfortunately, no
study correlating microbiological cure for UTI and fT > MIC
ratio for meropenem, ertapenem, piperacilin/tazobactam
and ceftriaxone were found. Considering the target for
aminopenicillin similar to the drugs included in this study,
those results might not be applicable on real life scenario
since an 8 g/mL MIC for meropenem and a 64 g/mL MIC
for piperacillin/tazobactam would be considered interme-
diate based on CLSI breakpoints, and a 16 g/mL MIC  for
l AUC:MIC for ciproﬂoxacin 400 mg  q12h against
R at varying total AUC:MIC exposures
100 125 150
80.05% 77.63% 76.76%
59.03% 56.73% 55.9%
i s . 2 0
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ceftriaxone, resistant. For renal tissue infection, the serum or
plasma concentration is a useful marker for the antibiotic con-
centrations in the renal tissue.19 As Pd targets for beta-lactams
in severe UTI are not well elucidated, for the present simu-
lation we  considered the established targets for bloodstream
infections.
Initially, we  estimated the variability for the Pk parameters
derived from healthy volunteers. Pk data from critical patients
were chosen for piperacillin/tazobactam and ceftriaxone due
to a lack of published reports which met  the inclusion crite-
ria for our study. DeRyke et al.,18 found CFR largely similar
for piperacillin/tazobactam whether Pk of patients or those
of healthy volunteers were used. Concerning ceftriaxone, in
spite of a weak increase of Vc and wide inter-patient variabil-
ity observed in critical patients, total serum concentrations
were similar to that observed in normal patients.26
Current recommendation advises not to prescribe
ciproﬂoxacin as empirical treatment for UTI if local resistance
exceeds 10%.5 Surveillance studies had already demon-
strated that ciproﬂoxacin resistance in Brazil overcomes
such percentage.18,19 Our study corroborates epidemiological
ﬁndings, which impacts on a low probability of achieving a
bactericidal exposure (CFR of 77.6% for outpatients and 56.7%
for inpatients considering an AUC/MIC target of at least 125).
Even if lower Pd targets were chosen, CFR stayed consistent
(≤5% decreases).
Based on the simulated PTAs ciproﬂoxacin should be pre-
scribed only when MIC  was equal or below 0.25 g/mL, despite
the susceptibility threshold currently considered. Inconsis-
tency between susceptibility and the predicted efﬁcacy of
antimicrobials has already been reported since CLSI-deﬁned
breakpoints for Gram negative bacilli might overestimate sus-
ceptibility in two to fourfold greater than those estimated by
Pd simulations.27
Ceftriaxone is a good option to treat severe UTI infection in
outpatients based on our simulations. Although dissemina-
tion of clones producing ESBL of community-acquired E. coli
infections were already reported intercontinentally,8 almost
all outpatient isolates were susceptible to ceftriaxone. We
observed a high percentage of non-susceptibility against cef-
triaxone (25.7%) in inpatient isolates, which decreases the
probability of achieving bactericidal exposures (76.9%) with
this regimen.
In this analysis, piperacillin/tazobactam, ertapenem and
meropenem achieved the highest CFRs in both scenarios. Pre-
vious Pk/Pd studies also found a high likelihood of achieving
optimal Pd target exposure for meropenem against E. coli
isolates.17,18,27
Similar to the derived result from Pd simulation of
ciproﬂoxacin, ertapenem presented a fourfold discrepancy
between CLSI deﬁned breakpoint and those derived from
stochastic determination. Although ertapenem had similar
in vitro activity to meropenem, its ability to achieve high bac-
tericidal Pd exposure will depend on the presence of a highly
susceptible population,17 which was reported in this study.
In spite of high CFR observed in present study, lower CFRs of
piperacillin/tazobactam against E. coli isolates was previously
demonstrated.24 Beta-lactam/beta-lactam inhibitor combina-
tion is an effective option to treat ESBL – E. coli bloodstream
infection originating from the urinary tract and should be 1 4;1  8(5):512–517
considered a reasonable alternative to carbapenems if active
in vitro.21
Certain assumptions are made for analyses performed with
Monte Carlo simulations. First, although the resistance rates
in our study were similar to previous surveillance studies, it
may not reﬂect isolate frequency and/or susceptibilities at all
institutions. Second, we  used Pk models derived from healthy
and infected adult patients, most of whom had normal renal
function. Dose adjustments might be necessary to attain sim-
ilar results for patients with renal insufﬁciency or pediatric
population. Finally, further studies are required to elucidate
the Pd threshold for ciproﬂoxacin and beta-lactams necessary
to provide microbiological cure in UTIs.
On the basis of this model using microbiology data from
outpatient and inpatient urinary isolates, standard doses of
beta-lactams were predicted to deliver sufﬁcient Pd exposure
for outpatients. In contrast, the low probability predicted for
ceftriaxone suggests that this drug should not be prescribed
in patients who have history of recent hospitalization, early
onset of in-hospital E. coli bacteremia or are in close relation-
ship with healthcare units. Ciproﬂoxacin prescription should
be discouraged even in community-acquired severe ITU.
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